A groundbreaking new drug has been approved on the NHS, and it could benefit hundreds suffering from one of the most aggressive forms of breast cancer.
It’s been revealed this week that NHS bosses have struck a deal with the manufacturers of the drug pembrolizumab, and have now been given the greenlight to treat around 1,600 patients in England who are suffering from triple negative breast cancer – which is one of the rarest and most aggressive forms of the disease.
Triple negative breast cancer accounts for around 15% of all cases, and is responsible for a quarter of all breast cancer deaths.
According to the charity Breast Cancer Now – which promotes cancer research, and offers support to sufferers – triple negative breast cancer is a particularly common form in those under 40, black women, and those who have inherited the BRCA gene.
Triple negative breast cancer patients have a shorter survival time than those with other forms of the disease, and typically, the risk of it returning and spreading to other parts of the body in the first few years after treatment is higher than for other cancer suffers.
ADVERTISEMENT
But now, scientists say that for those taking the new drug – which is a form of immunotherapy, and will be used alongside chemotherapy before surgery – the likelihood that the cancer will disappear, and the time before cancer returns, will increase.
Pembrolizumab will be one of just a few treatments that currently exist for triple negative breast cancer.
ADVERTISEMENT
Up to 1,600 of those affected by high risk triple-negative breast cancer a year are set to benefit from access to the treatment, called pembrolizumab, on the NHS.
Amanda Pritchard, the chief executive of NHS England, said the rollout of pembrolizumab – which she called “an innovative, potentially life-saving treatment” – was “fantastic news”, and said that it represented “a hugely significant moment for women”.
“It will give hope to those who are diagnosed and prevent the cancer from progressing, allowing people to live normal, healthy lives,” she added.
Breast Cancer Now has also hailed the approval of the new treatment.
“This new treatment can potentially lead to any detectable cancer disappearing by the time of surgery, meaning patients will then possibly face less invasive, breast-conserving surgery,” said Baroness Delyth Morgan, chief executive of Breast Cancer Now.
“By significantly reducing the likelihood of breast cancer recurring or spreading to other parts of the body where it becomes incurable secondary breast cancer, this treatment brings precious hope of more lives potentially being saved from this devastating disease.”
Arrest made after 14-year-old boy found in critical condition on Market Street
Daisy Jackson
An arrest has been made after a teenage boy was found unresponsive on Market Street in Manchester city centre.
Detectives believe that the boy, 14, was approached by seven males who stole a designer jacket from him.
Following the altercation, he went into cardiac arrest and was rushed to hospital in a critical condition.
Thankfully, the teenager is continuing to recover well.
Detectives from Manchester City Centre Criminal Investigation Department confirmed that an 18-year-old male was arrested yesterday, Thursday 20 February.
He has been arrested on suspicion of robbery and remains in police custody.
Detective Inspector Mark Astbury of GMP’s City Centre Criminal Investigation Department, said: “We hope the victim can continue his recovery following what must have been a terrifying ordeal for him.
“Officers are fully investigating all aspects of this shocking incident that has left a man with serious injuries in hospital.
“Our work doesn’t stop here, we are continuing to investigate this incident and information from the public plays an incredibly important role in our investigations and I ask that the community keep talking to us and keep sharing their concerns with us so our teams can act.”
If you have any information, contact GMP 101 or 0161 856 4305 quoting log 2854 of 16/2/25.
Comedy is being prescribed instead of antidepressants as part of UK trials
Emily Sergeant
Trials are currently underway to see if comedy could be an alternative to antidepressants as a way to reduce NHS costs.
UK tech company Craic Health has secured important funding for its ‘comedy on prescription’ project that’s aimed at helping the Government work with the comedy industry, communities, and organisations on comedy-based social prescriptions in the hope that they can solve financial struggles within the NHS.
The groundbreaking scheme uses stand-up shows and workshops to help people who are isolated, lonely, and vulnerable.
Craic believes comedy is an ‘untapped opportunity’ to improve health and wellbeing, and has a goal to make comedy easier to access, so that it can help communities experience its mental health and social benefits.
To achieve this, the company has started trialling Comedy-on-Prescription experiences in the UK – starting in London, with the potential for expansion – which includes things like curated comedy panel game show events and workshops, and general stand-up comedy shows at some of the capital’s world-famous venues.
Comedy is being prescribed instead of antidepressants as part of UK trials / Credit: Wikimedia Commons
“Mental health issues like loneliness, isolation, and stress are more common than ever,” the company explains.
“So much so that it’s projected that by 2030, mental health problems, particularly depression, will be the leading cause of mortality and morbidity globally, [but] in this challenging world, comedy stands out as a universal language that breaks barriers.
“Research shows that comedy and laughter have powerful effects – they bring people together, create positive connections, and make life more enjoyable.”
Craic Health says that social prescribing, of which Comedy-on-Prescription is a part of, is all about inclusivity, which makes it making it suitable for people of all ages, backgrounds, and abilities.
Its focus is on personalised support, tailored to individual needs and preferences.
Emily Sergeant -
8th November 2022 
